FIGURE

Fig. 4

ID

ZDB-FIG-260414-17

Publication

Ablain et al., 2021 - SPRED1 deletion confers resistance to MAPK inhibition in melanoma

Other Figures

All Figure Page

Back to All Figure Page

Fig. 4

SPRED1 loss confers resistance to BRAF inhibition in BRAF-driven zebrafish melanoma in vivo and is associated with acquired resistance to targeted therapy in a patient with melanoma. (A) Representative pictures of zebrafish bearing BRAF/tp53 or BRAF/tp53/spred1 tumors and treated daily with 5 µM dabrafenib for 14 d. Scale bar, 1 cm. (B) Quantification of tumor size after 14 d of dabrafenib treatment relative to tumor size before treatment in zebrafish with BRAF/tp53 (n = 13) or BRAF/tp53/spred1 (n = 9) tumors. Pooled data of three independent experiments. **, P = 0.01, two-tailed t test. (C) Circos representation of chromosome 15 copy-number changes of four tumors from a patient who was treated with and responded to dabrafenib plus trametinib. The outermost layer represents the chromosomal regions of chromosome 15, and the inner heatmaps indicate copy-number changes (log2 ratio) averaged in 1-kb genomic windows (from inner to outer: baseline, DD-DP1, DD-DP2, and DD-DP3). Arrow indicates the location of SPRED1.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Fish:	mitfa^w2/w2; mpv17^a9/a9 + CRISPR1-cdkn2a/b + CRISPR1-tp53 mitfa^w2/w2; mpv17^a9/a9 + CRISPR1-cdkn2a/b + CRISPR1-spred1 + CRISPR1-tp53
Condition:	chemical treatment by environment: dabrafenib
Knockdown Reagents:	CRISPR1-cdkn2a/b CRISPR1-spred1 CRISPR1-tp53
Observed In:	melanocyte
Stage:	Adult

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Exp. Med.